Drug makes struggling to set up next year's business plan

Tougher anticorruption measures to be slapped by the Fair Trade Commission (FTC), along with the government's relentless slash on drug prices, are casting a shadow over drug makers' business program next year, fueling concerns that domestic pharmaceutical industry could be shattered.

"If we go in that direction, we have to come up with something more dramatic. The selling of promising OTC pr...